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Insights into cancer genetics can lead to therapeutic
opportunities. By cross-referencing chromosomal
changes with an unbiased genetic screen we iden-
tify the ephrin receptor A7 (EPHA7) as a tumor
suppressor in follicular lymphoma (FL). EPHA7
is a target of 6q deletions and inactivated in 72%
of FLs. Knockdown of EPHA7 drives lymphoma
development in a murine FL model. In analogy
to its physiological function in brain develop-
ment, a soluble splice variant of EPHA7 (EPHA7TR)
interferes with another Eph-receptor and blocks
oncogenic signals in lymphoma cells. Consistent
with this drug-like activity, administration of the
purified EPHA7TR protein produces antitumor ef-
fects against xenografted human lymphomas. Fur-
ther, by fusing EPHA7TR to the anti-CD20 antibody
(rituximab) we can directly target this tumor sup-
pressor to lymphomas in vivo. Our study attests
to the power of combining descriptive tumor geno-
mics with functional screens and reveals EPHA7TR
as tumor suppressor with immediate therapeutic
potential.554 Cell 147, 554–564, October 28, 2011 ª2011 Elsevier Inc.INTRODUCTION
Insights into the molecular pathogenesis of cancer have led to
successful therapies. Recent technological advances greatly
facilitate the genome-wide detection of genetic and epigenetic
changes in cancer cells. For example, sequencing studies have
cataloged somatic mutations that occur in several cancers and
paired-end sequencing and array-CGH studies provide a
genome-level view of complex genomic aberrations that occur in
tumorigenesis (Velculescu, 2008). These studies have revealed
a diversity of genetic changes that likely account for some of the
clinical heterogeneity seen in pathologically similar tumors. Anal-
yses of larger numbers of patient samples have also uncovered
common and recurrent changes that may be considered as key
drivers of malignant transformation (Chin and Gray, 2008).
Notably, tumors often acquire complex genomic aberrations
including gains and losses of large sections or even entire chro-
mosomes. Identifying the target gene(s) from such complex
genomic changes remains a significant challenge. RNA-interfer-
ence (RNAi) technology has greatly facilitated loss-of-function
studies in mammalian cells and even in animal models (Dickins
et al., 2005; McCaffrey et al., 2002). Moreover, the adaptation of
RNAi technology to genetic screens enables rapid and unbiased
studies of gene inactivation. Such screens offer a powerful tool
to identify important cancer genes based on their biological func-
tion. Insights into the genetics of diffuse-large B cell lymphoma
(DLBCL) are successful examples of this strategy (Bidere et al.,
2009; Lenz et al., 2008; Shaffer et al., 2008). The combination of
tumor genomics with functional screens can distinguish
‘‘passenger’’ from ‘‘driver’’ mutations and unmask haplo-insuffi-
cient tumor suppressors that may not be obvious from the
genomic data alone. Therefore, cross-referencing genomic data
with genetic screens can facilitate the discovery of important
cancer genes that may be missed based on genomics alone
(Ngo et al., 2011; Oricchio et al., 2010; Zender et al., 2008).
Follicular lymphomas (FL) pose a significant clinical problem
because they are among the most common Non-Hodgkin’s
lymphoma and are considered incurable by standard chemo-
therapy approaches (Relander et al., 2010). Clinically, FLs are
characterized by slow and persistent growth with eventual
progression to an aggressive and rapidly spreading disease
that resembles DLBCL. The inclusion of the anti-CD20 antibody
(rituximab) has improved the outcome of chemotherapy (Malo-
ney, 2003). However, in eligible patients bone marrow transplan-
tation still remains the only curative option (Barr and Lazarus,
2008). Genetically, FLs are characterized by the translocation
t(14;18)(q32;q21) that causes increased expression of the antia-
poptotic BCL2 protein. BCL2 expression in germinal center
B-lymphocytes is considered the initiating lesion of FL (Bende
et al., 2007). Increased BCL2 is not sufficient for tumor develop-
ment or progression and additional genetic events are required
(Bende et al., 2007). Recurrent lesions in FL include amplification
of c-MYC, loss of p53, and frequent deletions affecting large
segments of chromosome 6q. These changes have also been
associated with early transformation into an aggressive disease
and shortened patient survival (Gaidano et al., 1992; Nanjangud
et al., 2007; Offit et al., 1993). Deletions affecting chromosome
6q also occur in other lymphoid cancers, for example in DLBCL,
where some of targets of the 6q deletion have been identified.
These include the BLIMP1/PRDM1 gene that controls terminal
lymphocyte differentiation and TNFAIP3/A20, a regulator of
NFkB signaling (Calado et al., 2010; Compagno et al., 2009;
Kato et al., 2009; Mandelbaum et al., 2010; Pasqualucci et al.,
2006). The molecular events and genetic targets of 6q deletions
in FLs are not understood and potentially insight into the patho-
genesis of FL can inform mechanism-based therapies.
Our study produced actionable insight into the genetics of
FL. By cross-referencing tumor genomic data with an unbiased
loss-of-function screen, we identified EPHA7 as a tumor sup-
pressor that is shed from germinal center B cells and lost in
FL. We confirmed its tumor suppressive function in a genetically
and pathologically accurate mosaic model of FL. Moreover, we
defined the molecular mechanism of EPHA7 action and devel-
oped an antibody-targeted delivery system for the restitution of
EPHA7 in a xenograft system. Hence, our study highlights the
power of functional genomics in cancer gene discovery, and
we demonstrate how genetic insights can be translated into
therapies.
RESULTS
A Functional Genomics Study of Follicular Lymphoma
We conducted a systematic functional genomics study into the
molecular pathogenesis of FL (Figure 1A). First, we analyzed64 FLs representing all pathological grades I-III (Grade I:
n = 21; II: n = 20, IIIa: n = 16, IIIb: n = 7) by array-CGH. Overall,
we observed 92 common regions of change. We defined a
common change as gains or losses occurring in > 10% of cases.
In detail, 38 common changeswere tumor specific and not found
in the reference DNA, four represented physiological changes
(e.g., B cell receptor rearrangements), and 50 were previously
identified common copy number variations (CNVs) (Figure 1B).
Deletions affecting chromosome 6q11-27 were the most
common losses and occurred in 23% of FLs (15/64 cases).
This is consistent with previous cytogenetic studies (Gaidano
et al., 1992; Hauptschein et al., 1998; Offit et al., 1993). More-
over, 6q deletions have been linked to patient survival in FL
indicating the presence of fundamentally important tumor
suppressor(s) in this region (Gaidano et al., 1992; Nanjangud
et al., 2007; Offit et al., 1993). Individual cases showed a hetero-
geneous pattern and typically had large, hemizygous losses of
6q affecting many genes (Figure S1 available online). Cumulative
analyses of all cases revealed common regions of deletion
(CRDs) that ranged from 5kb (CRD11) to 27Mb (CRD4) and
harbored between 1 and 78 genes (Figures 1C and 1D). Almost
all deletions were hemizygous and two small regions of apparent
homozygous loss within the CRD4 and CRD11 regions did not
affect any genes directly (Table S1, Table S2, and Table S3).
Thus, we find a complex pattern of large and hemizygous dele-
tions affecting 6q in FL, which suggests the presence of multiple
tumor suppressor genes, however an analysis of the genomic
data does not directly pinpoint any specific target gene.
A Deletion-Specific RNAi Screen to Identify Candidate
Tumor Suppressors at Chromosome 6q
Given the complexity of 6q deletions in FL, we wondered
whether an unbiased deletion-specific loss-of-function screen
could point us to potential tumor suppressor genes. We con-
structed a library of 260 shRNAs against 84 genes (1-7 shRNAs
per gene) in anMSCV-based, GFP-expressing vector (Table S4).
For our screen we used non-transformed murine pro-B lympho-
cytes engineered to express increased levels of Bcl2 as a trac-
table surrogate in vitro system. We screened the 6q deletion
library for shRNAs that could protect the lymphocytes from
cytokine (IL-3) depletion (Mavrakis et al., 2010) (Figure 2A).
Briefly, we partially transduced the FL5-12/Bcl2 cells with the
pooled 6q-deletion library or empty vector and monitored for
enrichment of GFP/shRNA expressing cells (Figure 2B). We
identified the shRNAs in the enriched population by subcloning
and sequencing. A count of clones representing each shRNA
revealed a distribution consistent with an enrichment of specific
shRNAs (Figure 2C). We then individually re-tested each shRNA
that was identified in the enriched cell population using the same
assay and confirmed a protective effect for shRNAs targeting
Tnfaip3/A20 and EphA7 (Figure S2A). Three additional EphA7
shRNAs reduced EPHA7 protein levels and re-produced this
protective effect, which was reversible by expressing the human
EPHA7 cDNA that is not recognized by the murine shRNA
(Figures S2B–S2D). EphA7 knockdown also facilitated faster
recovery of cell cycle progression following depletion and re-
addition of IL-3 in vitro (Figure 2E). Tnfaip3/A20 has been impli-
cated as a tumor suppressor in the activated B cell (ABC) typeCell 147, 554–564, October 28, 2011 ª2011 Elsevier Inc. 555
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Figure 1. Oncogenomic Study to Identify Tumor Suppressor Genes
in Follicular Lymphoma
(A) The study design combines genomic tumor analyses with an RNAi screen
and validation in murine models and in xenografts.
(B) Array-CGH analysis of 64 follicular lymphomas showing frequencies of
genomic gain (red) and loss (blue) across the genome.
(C) High resolution depiction of recurrent gains (red) and losses (blue) affecting
chromosome 6q, indicated are common regions of deletion (CRDs found
in > 10%).
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Figure 2. A 6q-Deletion-Specific RNAi Screen Functionally Identifies
EPHA7 as a Candidate Tumor Suppressor Gene
(A) Design of a pooled, deletion-specific shRNA library screen in a surrogate
model (immortalized FL5-12/Bcl2 cells).
(B) FACS profiles for GFP showing enrichment of cells expressing the shRNA
library (and the GFP reporter) following IL-3 depletion. See also Figure S2.
(C) Absolute number and identity of shRNA sequences retrieved from the
enriched population.
(D) EPHA7 and TNFAip3 map to the CRD4 and CRD9 in FL.
See also Figure S1.
556 Cell 147, 554–564, October 28, 2011 ª2011 Elsevier Inc.of DLBCL (Compagno et al., 2009; Kato et al., 2009; Novak et al.,
2009; Schmitz et al., 2009). The Eph-receptor A7 (EphA7) is
a surprising and new candidate gene. Looking back at the
genomic data, we find that EPHA7 and TNFAIP3 are affected
by common deletions in FL, and fall into the CRD4 and CRD9
region, respectively (Figure 2D and Figures S1B and S1C).
BLIMP1/PRDM1 has been implicated in DLBCL (Calado et al.,
2010; Mandelbaum et al., 2010; Pasqualucci et al., 2006), but
fell outside the common region of deletion and did not emerge(D) Mapping of CRDs. The observed 6q deletions are typically large and
hemizygous and do not readily identify a target gene.
See also Figure S1.
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Figure 3. EphA7 Opposes Tumor Development in a Murine Model
of FL
(A) A mosaic model of FL based on vavPBcl2 transgenic mice.
(B) Tumor latencies for animals receiving vavPBcl2 transgenic HSCs trans-
duced with empty vector (black, n = 11), or shRNAs against EphA7 (red, n = 18)
and p53 (green, n = 9) or overexpressing c-Myc (blue, n = 7).
(C) Immunoblot on FACS purified vavPBcl2 lymphoma cells expressing vector
or an shRNA against EphA7 and probed as indicated.
(D) Microscopic pathology and immunohistochemistry of vavPBcl2 lym-
phomas expressing the indicated constructs, red arrows indicate infiltrating
tumor cells.
See also Figure S3.from our screen (Figure 2D and Figure S2A). Hence, our RNAi
screen identifies a known tumor suppressor TNFAIP3/A20
(Compagno et al., 2009), and points to the ephrin receptor A7
(EPHA7) as a new candidate tumor suppressor gene.
EphA7 Acts as a Tumor Suppressor in a Murine Model
of Follicular Lymphoma
Mosaic mouse models of cancer enable the rapid functional
assessment of genetic interactions in tumorigenesis (Heyer
et al., 2010). The vavPBcl2 model closely recapitulates the
genetics andmorphology of human FL (Egle et al., 2004). In order
to directly test the role of EphA7 in FL we transduced vavPBcl2
transgenic hematopoietic progenitors (HSCs) with retroviral
shRNA vectors and transplanted these genetically engineered
cells into irradiated recipients (Wendel et al., 2004) (Figure 3A).
Ninety percent of controls remained tumor free for > 100d (vector
n = 11). c-MYC and p53 have established roles in FL transforma-
tion (Nanjangud et al., 2007). Accordingly, we find that enforced
c-Myc expression (p < 0.01, n = 7) and also p53 knockdown
(p < 0.01, n = 9) accelerated lymphomagenesis in vivo. Knock-
down of EphA7 had a similar effect on tumor latency as p53
inactivation (p < 0.01, n = 18) (Figure 3B). Immunoblots on puri-
fied vavBcl2 lymphoma cells readily confirmed efficient loss of
EphA7 expression in vivo, by contrast EphA7 was abundantly
expressed in murine splenocytes and HSCs (Figure 3C and Fig-
ure S3A). A second shRNA against EphA7was similarly enriched
during lymphomagenesis in vivo (Figure S3B). Hence, EphA7
knockdown promotes lymphoma development in the vavPBcl2
transgenic model of FL.
A detailed pathological analysis of the vavPBcl2 tumors
confirmed key features of human follicular lymphomas. In partic-
ular, the lymphomas retained the typical follicular structures,
showed expression of PNA, a marker indicating a germinal
center B cell phenotype, and had lowKi-67 indicating slow prolif-
eration like human FLs (Figure 3D, Figures S3C–S3E, and Table
S5). As expected these Bcl2 expressing tumors showed little or
no apoptosis by TUNEL. The c-Myc expressing tumors were
notably different and grew in a diffuse pattern that resembled
transformed FLs or aggressive DLBCL. These tumorsmay repre-
sent the aggressive transformation that is also seen in human FL.
All tumors expressed B cell markers (B220, CD19), and had
varying degrees of T cell infiltration (Table S5) (Egle et al.,
2004). Further supporting the germinal center origin of themurine
lymphomas, sequencing of the immunoglobulin JH4 intron
confirmed somatic hypermutation (SHM) that is also seen in
human FL (Table S6) (Egle et al., 2004; Mandelbaum et al.,
2010; McBride et al., 2008). PCR analysis of the immunoglobulin
heavy chain locus confirmed clonal origin of tumors (Figures
S3C–S3E) (Egle et al., 2004). Thus, the mosaic model based on
the vavPBcl2 transgenic mice retains key features of human FL
and reveals that EphA7 behaves as a tumor suppressor in follic-
ular lymphomagenesis.
EPHA7 Expression Is Lost in 72% of Follicular
Lymphomas
In our array-CGH analysis we found that EPHA7 is affected by
frequent hemizygous 6q deletions. We wondered whether
EPHA7may also be subject to epigenetic silencing or mutationalinactivation or if it acts as a haploinsufficient tumor suppressor.
We initially noted a differential reduction of EPHA7 mRNA
expression levels in lymphomas compared to germinal center
(GC) B cells, which are the normal counterpart and cell of originCell 147, 554–564, October 28, 2011 ª2011 Elsevier Inc. 557
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Figure 4. EPHA7 Is Differentially Silenced in FLs and Expressed in
Germinal Center B Cells
(A) qRT-PCR results for EPHA7 in purified B cells from reactive tonsils (T), GCB
cells (GC), purified B cells from follicular lymphomas (FL), and Burkitt’s
lymphomas (BL) (mean +/ standard deviation; p (tumor versus normal) < 0.05
for FL and BL).
(B) Immunohistochemical detection of the EPHA7 protein in a normal tonsil.
(C) Representative section of tissue microarrays (TMA) representing 322
human FLs and stained for EPHA7.
(D and E) Mass-array analysis of EPHA7 promoter methylation in 32 follicular
lymphomas (D), and 16 human lymphoma lines (E) and positive / negative
controls (Ctrl); the color scale indicates the degree of methylation (Red: 0%;
yellow: 100%).
(F) qRT-PCR of EPHA7mRNA levels in human lymphoma cell lines treatedwith
50aza-20-deoxycytidine (Aza); for all cell lines: p(untr. versus Aza.) < 0.01).
See also Figure S4.
558 Cell 147, 554–564, October 28, 2011 ª2011 Elsevier Inc.of these tumors (Klein and Dalla-Favera, 2008). In detail, qRT-
PCR showed decreased EPHA7 mRNA levels in purified
lymphoma cells (FL: 41 of 50 (82%); BL: 4 of 6 (67%)) compared
to GC B cells or tonsils (p(B cell versus lymphoma) < 0.02) (Figure 4A).
In our collection, reduced levels of EPHA7 were significantly
associatedwith tumor grade, which is linked to clinical outcomes
(Figure S4A). We easily detected cytpolasmic EPHA7 in normal
tonsils by immunohistochemistry. By contrast, EPHA7 expres-
sion was completely absent in 231 of 332 (72%) of FLs samples
on a tissuemicroarray (TMA) (Figures 4B and4Cand Figure S4B).
Hence, EPHA7 protein expression closely resembled the results
of our qRT-PCR analysis.
Loss of EPHA7 expression in lymphomas was due to differen-
tial promoter methylation. Mass-array analysis on 32 primary FLs
and 16 lymphoma cell lines revealed extensive CpG island
methylation (Figures 4D and 4E and Figures S4C–S4E). We
confirmed differential epigenetic silencing in normal GC B cells
(n = 9) and lymphomas (FL; n = 9 and DLBCL; n = 155; lymphoma
lines; n = 24) using the HELP (HpaII tiny fragment enrichment by
ligation-mediated PCR) assay for methylation detection (Fig-
ure S4D and S4E). Accordingly, in vitro treatment of human
lymphoma cells with 50Aza-20-deoxycytidine caused re-expres-
sion of EPHA7 (Figure 4F). EPHA7 silencing occurs differentially
in lymphomas and not in GC-B cells. Therefore silencing cannot
be attributed to cellular differentiation stage. Consistent with our
observations in FL and in DLBCL, differential EPHA7 silencing
has been reported in murine lymphomas arising in Tcl1 trans-
genic animals and in human B-lymphoblastic leukemia (B-ALL)
(Dawson et al., 2007; Kuang et al., 2010). These findings may
indicate a broader role for EPHA7 in lymphocyte malignancies.
While somatic mutations affecting EPHA7 have been reported
in lung cancer (Ding et al., 2008), we did not detect EPHA7
mutations in the 24 FL cases we analyzed (not shown). Hence,
EPHA7 acts as a tumor suppressor in vivo and is targeted by
genomic deletions and differential epigenetic silencing in human
lymphomas.
EPHA7 Blocks Oncogenic Signals in Human
Lymphoma Cells
The role of ephrin signaling in cancer is unclear and both onco-
genic and tumor suppressive functions have been discussed
(Noren et al., 2006; Pasquale, 2010). Ephrin receptors are
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Figure 5. EPHA7FC Binds to EPHA2 and Blocks
Oncogenic Signals in Lymphoma Cells
(A) Lysates and conditioned media from FL5-12/Bcl2 cells
expressing vector, an shRNA against EphA7 (shEphA7), or
full length EphA7 (EphA7FL) probed with an antibody
against EPHA7.
(B) Immunoprecipitation of lysates from Raji cells treated
with EPHA7FC (FC-tagged ectodomain of EPHA7) or FC, IP
with anti-EPHA7 and probed against EPHA7 and EPHA2.
(C) ELISA assay for EPHA2 phosphorylation on Raji cells
treated with EPHA7FC or vehicle (FC).
(D) Immunoblot on lysates of Raji cells treated with vehicle,
EPHA7FC (5mg) or an siRNA against EPHA2.
(E) Immunoblot on Raji cells treated with 5 mg/ml EPHA7FC
for the indicated times.
(F) Model of the EPHA2 – EPHA7TR interaction based on
the known structure of EPHA2 and its homology with
EPHA7 (LBD, ligand binding domain, EGF, EGF-like
domain, FNIII, fibronectin domain).
See also Figure S5.tyrosine kinases that form dimers and are activated upon contact
with ephrin expressing cells (Himanen et al., 2010; Seiradake
et al., 2010). In this manner ephrin signaling is thought to mediate
cell-cell signals in a variety of physiological contexts (Pasquale,
2010). Notably, alternate splice forms have been described for
the murine and human EPHA7 genes that result in truncated
proteins that lack kinase activity and can be shed from the cell
surface (Dawson et al., 2007; Holmberg et al., 2000; Valenzuela
et al., 1995). Alternate EPHA7 splicing has an important role in
embryonic development, where expression of the short variant
and its binding to the full-length EPHA7 receptor mediate
a switch from cellular repulsion to adhesion during neural tube
closure (Holmberg et al., 2000).
Normal B-lymphocytes express only a truncated EPHA7
protein (EPHA7TR) and not the full-length receptor (Figure 5A).
Similarly, treatment of human SU-DHL-10 lymphoma cells with
the de-methylating agent 50aza-20-deoxycytidine results in
re-expression of only a truncated EPHA7TR protein that lacks
the intracellular domains (Figures S4F–S4I). Consistent with
potential shedding from the cell surface, we detect EphA7TR
not only in lymphocyte lysates, but also in conditioned media
from lymphocyte cultures, and also in the serum of volunteers
(Figure 5A and Figure S5A). Lymphomas and derived cell lines
do not express EPHA7 (Figure 4). However, Raji and DoHH2 cells
express another EPHA receptor, the homologous EPHA2
receptor. Immunoprecipitation shows that an FC-tagged
EPHA7 ectodomain protein (from hereon called EPHA7FC) can
bind to the EPHA2 receptor (Figure 5B and Figures S5B and
S5C). In vitro treatment with EphA7FC further decreases
EPHA2 phosphorylation by ELISA, and both, EPHA7FC treatment
and EPHA2 knockdown by RNA interference lead to inhibition ofCell 147, 55ERK phosphorylation in lymphoma cell lines
(Figures 5C and 5D and Figures S5D and S5E).
Conversely, knockdown of EPHA7 using addi-
tional EphA7 shRNAs causes ERK activation in
B-lymphocytes, and this activation is reversed
with purified EPHA7FC protein (Figures S5F–S5I). Using a phospho-protein array we identified additional
signaling effects of EPHA7FC in lymphoma cells. Briefly, the array
confirmed ERK inhibition and showed that EPHA7FC blocks
several SRC family kinases including FYN, YES, FAK, SRC,
also STAT3 and others (Figures S5J and S5K). We confirmed
the effects on ERK, STAT3 and SRC phosphorylation by immu-
noblot and also noted some cell line specific differences (Fig-
ure 5E and Figures S5L and S5M). Hence, EPHA7FC acts, at least
in part, as a dominant, soluble inhibitor of EPHA2 signaling in
lymphoma cells.
Next, we examined the possibility that EPHA7 might interact
with additional EPHA receptors or ephrin ligands. Gel shift
revealed that purified EPHA7FC could interact with EPHA2
and also EPHA3 but not EPHA4 (Figure S5N). However, in FL
samples we only detected mRNA expression of EPHA2 and
not EPHA3, and we confirmed EPHA2 protein expression by
staining the TMA (Figure S5O and data not shown). Ephrins are
the physiological ligands for Eph receptors and gel-shift showed
that purified EphA7FC can interact with ephrins A1, A4 and A5,
but not with ephrins A2 and A3 (Figure S5P). We detected signif-
icant expression of ephrins A1 and A3 in human FL samples
(Figure S5Q and data not shown). To discern the contribution
of ephrin binding to the signaling and antiproliferative effects of
EPHA7 in lymphoma, we mutated the ephrin binding domain
of EPHA7 (T105Q) (Figure S5R). The analogous mutation in
EPHA3 has been shown to selectively disrupt ephrin binding to
the receptor (Smith et al., 2004). The EPHA7 mutant (T105Q)
retained the ability to block ERK activation and had antiprolifer-
ative effects that were similar to the wild-type EPHA7 (Suppl.
Figures 5S, 5T). We cannot exclude that EPHA7 may also bind
additional surface molecules. Based on these data, the known4–564, October 28, 2011 ª2011 Elsevier Inc. 559
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Figure 6. Exogenous Administration of Purified EPHA7 Suppresses Human Lymphoma Xenografts
(A) Xenografted Raji lymphomas grown in the flank of NOD/SCIDmice and treated three times on alternate days by intra-tumoral administration of 20 mg EPHA7FC
(red circle) or vehicle (FC; black circle).
(B) Microscopic pathology on EPHA7FC treated and mock treated Raji lymphomas stained as indicated.
(C) Immunoblot on lysates of tumors treated with EPHA7FC or vehicle in vivo.
(D) Matched pair analysis of tumor volumes of eight (A-H) treated (red) and control (black) Raji lymphomas.
(E) Intravenous (i.v.) administration of vehicle (FC, black) or EPHA7FC (20mg, for 3 days, red) delays tumor development from 1x106 injected Raji lymphoma cells.
See also Figure S6.structure of EPHA2, and its homology with the EPHA7 sequence
(51%) and domain structurewe built a structural model (Himanen
et al., 2010; Seiradake et al., 2010). The model suggests that the
EPHA2 receptor and EPHA7TRmay interact through several sites
in their Sushi and ligand binding domains, resulting in a hetero-
dimer that cannot undergo auto-phosphorylation and activation
(Figure 5F). In analogy to the function of EPHA7TR in nervous
system development (Holmberg et al., 2000), we propose that
EPHA7 acts as a decoy receptor that blocks EPHA2 activation
and oncogenic signals including ERK and SRC in lymphoma
cells.
EPHA7 Has Antitumor Activity against Xenografted
Human Lymphomas
Given that EPHA7TR can block oncogenic signaling molecules
and act as a tumor suppressor in a murine model, we wondered
whether the EPHA7TR protein had therapeutic activity against
xenografted human lymphomas. First, we examined the effects
of restoring EPHA7 by either retroviral expression or by direct
application of the purified EPHA7FC protein on human lymphoma
cells in vitro. In these experiments EPHA7 had powerful antipro-
liferative effects against Raji, DHL-10, DoHH2 and Karpas 422
cells in vitro (Figures S6A–S6E). In vivo we observed the most
striking effects upon local EPHA7 injection. The purified
EPHA7FC protein (20mg for 3 days), but not vehicle (Fc), caused
dramatic tumor regressions (n = 12; p(FC versus EPHA7) < 0.04) (Fig-
ure 6A and Figures S6F and S6G). Residual EPHA7FC treated560 Cell 147, 554–564, October 28, 2011 ª2011 Elsevier Inc.lymphoma xenografts showed extensive apoptosis, disrupted
architecture, and reduced ERK phosphorylation (Figures 6B–
6D). We also observed that systemic administration of EPHA7FC
via tail-vein injection (i.v. 20mg for 3 days) caused a significant
delay in the development of xenografted Raji lymphomas
(EPHA7FC: n = 5; Vehicle/Fc: n = 5; p < 0.05) (Figure 6E).
Targeted Tumor Suppressor Therapy
with an Anti-CD20-EPHA7 Fusion Protein
Next, we wondered whether fusing EPHA7 to the Fc-terminus of
an anti-CD20 antibody (rituximab) could further enhance its
therapeutic potential and selectively deliver the EPHA7 tumor
suppressor to the lymphoma cells in vivo (Figure 7A and Fig-
ure S7A). Initial characterization of the fusion antibody (anti-
CD20-EPHA7TR) revealed that it retained properties of both
proteins. Namely, the fusions recognized CD20+ Raji lymphoma
cells in vitro (Figure S7B), and the protein retained the ability to
block EPHA2 and ERK phosphorylation in vitro (Figure 7B and
Figure S7C). Moreover, the fusion antibody was more efficient
than anti-CD20 alone in slowing cell proliferation and in killing
Raji or FL-derived DoHH2 cells in vitro (Figures 7C and 7D and
Figures S7D and S7E). In vivo treatment with either anti-CD20
or the fusion antibody (1mg i.v. for 5 days) was well tolerated.
However, in Raji xenografts that had reached a size of > 1cm3
at the time of treatment only the fusion antibody was able to
produce complete responses (ex vivo tumor weight 0 – 30 mg)
in 3 of 7 animals. Residual tumors examined immediately
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Figure 7. Targeted Delivery of EPHA7 to Xenografted Lymphomas
Using an Anti-CD20-EPHA7 Fusion Antibody
(A) Schematic of the anti-CD20/EPHA7 fusion antibody.
(B) Immunoblot on Raji cells that were untreated (Untr.), treated with anti-CD20
(CD20), or anti-CD20-EPHA7TR fusion (CD20/E7).
(C) Proliferation of Raji cells treated as indicated (*denotes p(CD20 versus
CD20/E7 < 0.05).
(D) Apoptosis of Raji cells treated as indicated at 24 hr and 48 hr; asterisk and
double asterisks denote significance (p < 0.05).
(E) Mice bearing Raji xenografts (>1cm3) left untreated (Untr.) or given 1mg of
anti-CD20 (CD20) or anti-CD20-EPHA7TR (CD20/E7) for 5 days and collected
2 days after last treatment. Tumors (in matrigel) weighed ex vivo and classified
as complete response (CR): 0 – 30 mg, partial responses (PR): 30-100 mg; no
change (NC)/progressive disease (PD): > 100 mg.
See also Figure S7.following the last antibody administration confirmed reduced
ERK activation, and effects on apoptosis and proliferation by
TUNEL and Ki-67 stain as the most immediate effects of therapy
(Figure S7F). At higher doses (20mg) rituximab is curative against
xenografts (data not shown). However, when tested at the same
low dose (1mg for 5 days) the anti-CD20 antibody was less effec-
tive than the fusion protein and produced only partial responses
or slowed progression compared to vehicle (p = 0.039, Fisher’s
exact for all three groups) (Figure 7E).
Finally, we examined the potential toxicity of administrating
either the purified EphA7FC protein or the fusion antibody. Briefly,
animals treated with twice the therapeutic dose revealed no
overt toxicity at 24 hr or 7 days after treatment. Necropsy
revealed no macro- or microscopic organ damage, and serum
chemistry showed only marginally elevated glucose levels but
was otherwise unremarkable. Differential blood counts showed
a decrease in mean corpuscular hemoglobin in the absence
of frank anemia (Figure S7G). Hence, the EPHA7 protein has
well-tolerated in vivo tumor suppressive properties that can bedirected to xenografted human lymphomas using an anti-CD20
antibody.
DISCUSSION
Our study illustrates the power of combining tumor genomic data
with functional genetic screens and exemplifies the translation of
genetic insights into therapies. The size and hemizygosity of
chromosome 6q deletions in follicular lymphoma would typically
preclude the identification of a target gene based on genomic
analyses alone. By cross-referencing the genomic data with
the results of an unbiased, deletion-targeted loss of function
screen, we functionally identify the truncated EPHA7 receptor
as a soluble tumor suppressor in FL. We describe converging
lines of evidence including in vivo studies in a mouse model,
and in human lymphoma cell lines that EPHA7 acts as a tumor
suppressor in follicular lymphoma and is a promising candidate
for translational development.
We provide insight into themolecular pathogenesis of follicular
lymphoma (FL). FLs are characterized by the translocation
t(14;18)(q32;q21) that causes increased expression of BCL2,
which is considered an initiating event in the malignant transfor-
mation of germinal center B cells (Bende et al., 2007). However,
several facts indicate that elevated BCL2 is not sufficient for
lymphoma development. For example, the t(14;18)(q32;q21) is
often found in healthy individuals, we and others find a multitude
of genomic aberration in diagnosis samples of FL, and also the
long latency to lymphoma development in Bcl2 transgenic
animals indicate that additional events are required for lympho-
magenesis (Bende et al., 2007; Egle et al., 2004; Nanjangud
et al., 2007). Deletions affecting chromosome 6q11-27 are
particularly common in FL and can affect the outcome of treat-
ment in lymphoma patients (Johnson et al., 2009; Nanjangud
et al., 2007; Viardot et al., 2002). We find a complex pattern
of large and hemizygous 6q deletions in FL and most likely
this pattern suggests the presence of multiple and potentially
cooperating tumor suppressor genes. However the absence of
bi-allelic losses precludes the direct identification of a specific
target based on the genomic deletion data and may indicate
the presence of haploinsufficient tumor suppressors. We have
used a genetic screening approach to functionally identify tumor
suppressor genes in the 6q region. The screen uncovered
a surprising role for the ephrin receptor A7 (EPHA7) as a candi-
date tumor suppressor in FL. We confirm its ability to oppose
lymphomagenesis using a genetically and pathologically accu-
rate mouse model of the disease. We also demonstrate that
EPHA7 has dramatic antitumor effects on human lymphoma
cells. Further, an analysis of several hundred primary FL speci-
mens reveals differential silencing of EPHA7 in tumors, and
EPHA7 expression in germinal center B-lymphocytes, which
are considered the cell of origin and normal counterpart of these
lymphomas (Klein and Dalla-Favera, 2008). Hence, loss of
EPHA7 expression does not merely reflect cellular differentiation
or transformation, and instead EPHA7 inactivation directly
contributes to lymphomagenesis. Consistent with our findings
in FL, EPHA7 silencing has been observed in lymphomas arising
in Tcl1 transgenic animals, in human marginal zone lymphomas
(MZL), and in acute lymphoblastic leukemia (B-ALL) (DawsonCell 147, 554–564, October 28, 2011 ª2011 Elsevier Inc. 561
et al., 2007; Kuang et al., 2010). These data may suggest
a broader role for EPHA7 in lymphoid cancers. Deletions of chro-
mosome 6q have also been described in other types of
lymphomas. These lesions have been studied in detail in DLBCL,
where tumor suppressive activities have been shown forBLIMP1
and TNFAIP3 (Calado et al., 2010; Compagno et al., 2009; Kato
et al., 2009; Mandelbaum et al., 2010; Pasqualucci et al., 2006).
Inactivation of these genes has been specifically associated with
the activated B cells (ABC) type of DLBCL, but not the germinal
center type of DLBCL. Our screen confirms a cell survival func-
tion for TNFAIP3/A20, a negative regulator of NFkB signaling.
BLIMP1 fell outside the common region of loss in FL and did
not pass our screen, which does not probe effects on lympho-
cyte differentiation. The pattern of genomic loss suggests the
presence ofmultiple oftentimes haploinsufficient tumor suppres-
sors in this region and that these may cooperate in lymphoma-
genesis. We did not investigate these interactions, and decided
to focus on the soluble tumor suppressor EPHA7 because of its
potential for therapeutic application.
Ephrin receptors form a large family of receptor tyrosine
kinases with established functions in cell-cell signaling, embry-
onic development and neuro- and angiogenesis (Pasquale,
2008). In epithelial cancers both oncogenic and tumor suppres-
sive roles have been described for specific ephrin receptors
and their ligands (Dawson et al., 2007;Macrae et al., 2005; Noren
et al., 2006; Pasquale, 2010). Specifically, EPHA7 is frequently
silenced in gastric, colon and prostate cancers and somatic
mutations have been found in non-small cell lung cancer (Ding
et al., 2008; Pasquale, 2010). We now identify EPHA7 as a target
of recurrent deletions and differential epigenetic silencing in
lymphoma and we demonstrate its ability to oppose lymphoma
development in mice and kill human lymphoma cells. Notably,
normal B-lymphocytes express only a short splice variant of
EPHA7 (Dawson et al., 2007; Holmberg et al., 2000; Valenzuela
et al., 1995). The expression of EPHA7TR is completely lost in
over 70% of FLs, and is re-activated in human lymphoma cells
following 50azacytidine treatment. EPHA7TR is shed from normal
B cells and likely acts in an auto- and paracrine manner. Specif-
ically, the soluble EPHA7 protein binds to another Eph-receptor
(EPHA2) andblocks its activity anddownstreamsignals including
ERK and SRC kinases. Interestingly, this mechanism is reminis-
cent of EPHA7’s function in central nervous systemdevelopment
(Holmberg et al., 2000). Briefly, during neural tube closure the
short splice form of EPHA7 binds to and blocks the signaling
activity of the full-length EPHA7 receptor. In the brain, this inter-
action causes a switch from cellular repulsion to adhesion and
permits closure of the neural tube. In lymphocytes we do not
detect expression of the full-length EphA7 receptor, instead
these cells express the homologous full-length EphA2 receptor
and EphA7TR can bind and block the activity of that receptor.
Accordingly, knockdown of EPHA2 in lymphoma cells produces
the same effect as EPHA2 blockade with EPHA7TR. Disabling the
ephrin binding site on EPHA7 does not affect its signaling and
antitumor properties, however we cannot rule out that EPHA7
may alsobind other surface receptors.Wepropose amechanism
whereby the soluble EPHA7 protein is a decoy receptor that acts,
at least, in part by interfering with Eph-receptor dimerization,
auto-phosphorylation and signaling activity.562 Cell 147, 554–564, October 28, 2011 ª2011 Elsevier Inc.Our findings concerning EPHA7 are directly relevant to
lymphoma treatment. Tumor cells are highly sensitive to the
restoration of tumor suppressor genes and even brief reactiva-
tion can produce powerful therapeutic effects (Feldser et al.,
2010; Ventura et al., 2007; Xue et al., 2007). EPHA7 is especially
interesting in this regard because it encodes an extrinsic tumor
suppressor and can disrupt oncogenic signals emanating from
other Eph-A receptors. Accordingly, we find that exogenous
administration of EPHA7 produces powerful antitumor effects
against xenografted human lymphoma cells. To further enhance
the potential for clinical application we engineered a fusion anti-
body based on the anti-CD20 (Rituximab) antibody that is
already in clinical use. Specifically, we fused EPHA7 to the
anti-CD20 antibody, this allows us to deliver EPHA7’s tumor
suppressive activity directly to the CD20 expressing lymphoma
cells. The EPHA7-antibody fusion limits the potential for
unwanted off-target effects and has single agent activity against
lymphoma xenografts at very low concentrations. Potentially,
EPHA7TR may be active against other cancers with 6q loss or
amplifications of EPHA2. Further studies are needed also to
define a minimum tumor suppressive peptide, and to compare
its long-term efficacy to current anti-CD20-based therapies. In
summary, our study reveals EPHA7 as a tumor suppressor in
follicular lymphoma, and indicates a therapeutic strategy that
exploits the tumor suppressor hypersensitivity of these tumors.
EXPERIMENTAL PROCEDURES
Tumor Ascertainment
Sixty-four newly diagnosed FLs collected atMSKCC since 1984 and evaluated
by 3 hematopathologists, classified according to WHO criteria, were selected
based on diagnosis and presence of an abnormal karyotype. TMAs were con-
structed from a separate series of 322 follicular lymphomas treated at MSKCC
(see Extended Experimental Procedures for details).
Array-CGH
DNA from fresh frozen tissue or OCT-embedded tissue was analyzed on an
Agilent 244K oligonucleotide array and compared to human male DNA
obtained from Promega (Cat# G147A) as a reference. All genomic positions
described refer to UCSC May 2004 human reference sequence (hg17/NCBI
build 35). The modified CBS algorithm was used to identify segmental gains
and losses along the autosomes (see Extended Experimental Procedures for
details).
Cell Culture and Pooled shRNA Library Screen
FL5-12 murine lymphocytes were stably transduced with Bcl2 (FL5-12/Bcl2).
Briefly, the shRNA library was constructed by pooling 262 individually cloned
shRNAs and shRNAs were identified by sequencing upon enrichment of GFP
expressing cells (see Extended Experimental Procedures for details).
Generation of Mice
The vavPBcl2 mouse model of FL(Egle et al., 2004) and EmMyc lymphoma
model were adapted to the transplantation approach using retrovirally trans-
duced HSCs (Wendel et al., 2004). Data were analyzed in Kaplan-Meier format
using the log-rank (Mantel-Cox) test for statistical significance (see Extended
Experimental Procedures for details).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures,
seven tables, and seven figures and can be found with this article online at
doi:10.1016/j.cell.2011.09.035.
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